Foresite Capital Management III’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Foresite Capital Management III’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-380,530	Closed	-$1.1M	–	29
2017 Q2	$1.1M	Hold	380,530	–	–	0.36%	20
2017 Q1	$1.31M	Buy	380,530 +126,273	+50%	+$498K	0.5%	22
2016 Q4	$442K	Hold	254,257	–	–	0.19%	20
2016 Q3	$844K	Sell	254,257 -1	-0%	-$4	0.39%	15
2016 Q2	$1.09M	Sell	254,258 -48,477	-16%	-$219K	0.75%	15
2016 Q1	$1.7M	Buy	302,735 +2,735	+0.9%	+$35.5K	1.32%	18
2015 Q4	$5.16M	Buy	+300,000	New	+$7.15M	4.58%	9

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

OWIM

Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Foresite Capital Management III's OREX Position: Q3 2017 in Review

Foresite Capital Management III sold out of Orexigen Therapeutics, Inc. (OREX) in Q3 2017, closing a stake of 380,530 shares — an estimated $1.1M sold.

Foresite Capital Management III first reported a position in OREX in Q4 2015 and held it in 7 quarters. The position peaked at $5.16M in Q4 2015. 42 funds tracked by Wall St. Rank hold OREX as of Q3 2017.

Foresite Capital Management III reported no remaining Orexigen Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
Foresite Capital Management III sold 380,530 Orexigen Therapeutics, Inc. shares in Q3 2017, an estimated $1.1M.
Foresite Capital Management III first reported a position in Orexigen Therapeutics, Inc. in Q4 2015 and held it in 7 quarters.
Foresite Capital Management III's Orexigen Therapeutics, Inc. position peaked at $5.16M in Q4 2015.
42 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2017.

Based on Foresite Capital Management III's 13F filing for Q3 2017, filed 13 Nov 2017.